Keyword: Icahn School of Medicine at Mount Sinai
New biotech discoveries include CRISPR-induced conception and a biomarker for predicting breast cancer recurrences.
Researchers used the gene editing system CRISPR-Cas9 to discover a signature of resistance to BRAF inhibitors in melanoma.
After reprogramming a type of retinal cells, Mount Sinai scientists helped blind mice regain some visual function.
The past week’s biotech news included insight into how ApoE4 raises Alzheimer’s risk and a peptide vaccine for broad flu protection.
A "multi-omic" analysis of more than 900 donor brains linked the amount of herpes virus in a person's brain to the presence of Alzheimer's markers.
The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.
Scientists from the University of Chicago and Mount Sinai are exploring different methods of improving checkpoint-inhibiting cancer drugs.
A mutation in the tumor-suppressing gene PTEN causes uncontrolled growth in several types of cancer. Mount Sinai researchers found an approved rheumatoid arthritis drug that stops this growth in its tracks and could be a possible new treatment for aggressive cancers.
Endometrial cancer is becoming both more prevalent and more deadly, yet there are still no good screening methods to catch the disease in its earliest stages. Scientists at the Icahn School of Medicine at Mount Sinai in New York are working on a solution, and it lies in detecting genetic mutations in the lining of the uterus.
IBM scientists have come up with new lab-on-a-chip tech that separates bioparticles on a much smaller scale than previously possible, allowing for the earlier detection of cancer.